SCHEMBL31248428

SCHEMBL31248428

CCOC(=O)COc1ccccc1S(=O)(=O)CP(=O)(OCC)OCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.46
PTPN1 P18031 1/20 0.46
ABCB1 P08183 1/20 0.44
CASP3 P42574 1/20 0.44
CASP7 P55210 1/20 0.44
CASP9 P55211 1/20 0.44
ALDH1A1 P00352 4/20 0.43
NPSR1 Q6W5P4 3/20 0.43
LMNA P02545 3/20 0.43
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 2/20 0.43
MAPK1 P28482 2/20 0.43
TLR9 Q9NR96 2/20 0.43
NPC1 O15118 1/20 0.43
S1PR4 O95977 1/20 0.43
ITGA4 P13612 1/20 0.43
S1PR1 P21453 1/20 0.43
RAB9A P51151 1/20 0.43
GAA P10253 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21724689 0.88 L3MBTL1 (0.52) ALDH1A1MAPTSMN1; SMN2HPGDMAPK1
SCHEMBL15818796 0.79 USP2 (0.55) USP2PTPN1ABCB1CASP3CASP7
SCHEMBL15819886 0.78 USP2 (0.53) USP2PTPN1ABCB1CASP3CASP7
SCHEMBL21723076 0.78 NPSR1 (0.64) ALDH1A1NPSR1MAPTSMN1; SMN2HPGD
SCHEMBL21723738 0.78 MAPT (0.37) ALDH1A1NPSR1LMNAMAPTSMN1; SMN2
SCHEMBL21724298 0.76 NPSR1 (0.38) ALDH1A1NPSR1LMNAMAPTMAPK1
SCHEMBL15818015 0.76 USP2 (0.51) USP2PTPN1ABCB1CASP3CASP7
SCHEMBL2010417 0.75 USP2 (0.67) USP2PTPN1ABCB1CASP3CASP7
SCHEMBL31389219 0.74 POLB (0.37) PTPN1ALDH1A1NPSR1LMNAMAPT
SCHEMBL28653411 0.72 HPGD (0.49) ALDH1A1LMNAHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234207-B2 Halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative and use thereof CUREVERSE INCORPORATED (KR) 2025-02-25 US claimed
CN-112930345-B Novel halo- (3- (benzenesulfonyl) prop-1-ene) pyridine derivatives and use thereof 库尔维斯株式会社 2024-09-24 CN claimed
US-12234207-B2 Halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative and use thereof CUREVERSE INCORPORATED (KR) 2025-02-25 US disclosed
CN-112930345-B Novel halo- (3- (benzenesulfonyl) prop-1-ene) pyridine derivatives and use thereof 库尔维斯株式会社 2024-09-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234207-B2 Halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative and use thereof KEAP1, NFE2L2, NQO1 USP2 1972/4885PTPN1 2422/4885ABCB1 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.